Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes

D A Elmouchi1, E R Bates

  • 1Division of Cardiovascular Diseases, Department of Internal Medicine, University Hospital, University of Michigan, Ann Arbor, MI 48109, USA.

Minerva Cardioangiologica
|October 11, 2003
PubMed

Insights

Platelet glycoprotein (GP) IIb/IIIa inhibitors reduce ischemic events in high-risk acute coronary syndrome patients. Despite proven benefits, underutilization persists, highlighting a need for improved treatment strategies.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelet glycoprotein (GP) IIb/IIIa inhibitors are crucial in managing acute coronary syndromes.
  • These agents prevent fibrinogen binding and platelet aggregation, reducing ischemic complications.

Purpose of the Study:

  • To evaluate the efficacy of parenteral GP IIb/IIIa inhibitors in high-risk acute coronary syndrome patients.
  • To assess the current utilization patterns and identify barriers to therapy.

Main Methods:

  • Meta-analysis of 6 randomized controlled trials involving parenteral GP IIb/IIIa inhibitors.
  • Analysis of patient subgroups including those undergoing percutaneous coronary intervention, high TIMI risk score, elevated troponin, and diabetes mellitus.

Main Results:

  • Significant reduction in death and myocardial infarction observed in high-risk patient populations.
  • Identified underutilization of these agents despite guideline recommendations for specific indications.

Conclusions:

  • Parenteral GP IIb/IIIa inhibitors offer significant benefits for high-risk acute coronary syndrome patients.
  • Addressing underutilization is critical to improve patient outcomes; further research into optimal dosing is warranted.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...